The clinical outcome based on the treatment course factors in CLASSIC trial.

Proposal
7080

Title of Proposed Research

Lead Researcher

Hisaka Akihiro

Affiliation

Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan

Funding Source

Potential Conflicts of Interest

Data Sharing Agreement Date

19 May 2020

Lay Summary

The purpose of this research is to find factors that influence the efficacy of adjuvant chemotherapy for gastric cancer. Gastric cancer is the fifth most common cancer in the world and is a major cause of cancer-related death. In 2012, there were approximately 952,000 new cases of gastric cancer worldwide (631,000 men and 320,000 women) with 723,000 deaths (469,000 men and 254,000 women), making it the third-leading cause of cancer death globally in both sexes

Study Data Provided

[{ "PostingID": 4263, "Title": "*SANOFI-MO17527/L_9570", "Description": "A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma" },{ "PostingID": 5067, "Title": "ROCHE-MO17527 (L_9570)", "Description": "A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma" }]

Statistical Analysis Plan

Publication Citation